A new LMU study shows how proteins function reliably even without a stable 3D structure – and the crucial importance not only of short sequence motifs, but also of the chemical characteristics.

From the whirlwind start of the second Trump administration through the war in Iran, Americans have been put to a very difficult task: How are they to make sense of this cascade of events? Last fall, ...

A new LMU study shows how proteins function reliably even without a stable 3D structure—and the crucial importance not only of short sequence motifs, but also of chemical characteristics. Many ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Here Group Limited (NASDAQ: HERE) ('Here” or the 'Company”), an IP1-based pop toy company dedicated to creating beloved collectibles and trend-defining experiences, today announced its unaudited ...

Biologists at the National University of Singapore (NUS) have uncovered how the protein NuSAP safeguards tiny structures inside cells called centrioles, revealing a mechanism linked to developmental ...

An Arizona Supreme Court program allowing nonlawyers to own law firms has led to numerous consumer complaints. Several members of the program's oversight committee also have financial ties to firms ...

LOUISVILLE, Colo.--(BUSINESS WIRE)--Sierra Space, a proven defense-tech company delivering solutions for the nation’s most critical missions and advancing the future of security in space, announced ...

Student Success Programs has announced the launch of Purdue’s Basic Needs Program in place of what was Span Plan Nontraditional Student Services. The Purdue Basic Needs Program improves student ...

The last time I wrote an article on Structure Therapeutics Inc. (GPCR) it was in a Seeking Alpha article entitled "Structure Therapeutics: Potential To Have Best-In-class GLP-1 Agonist For Obesity ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...